Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown,
NY 10591
United States - Map
Phone: 914-789-2800
Fax: 914-789-2817
Website: http://www.progenics.com
Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York. Key Statistics
| |
| Progenics Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 1. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 3. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Mark R. Baker J.D.,
58
Chief Exec. Officer, Director, Member of Science & Technology Committee and Member of Strategy & External Technology Subcommittee | 688.00K | 0.00 | Dr. Paul J. Maddon M.D., Ph.D.,
53
Founder and Vice Chairman | 2.06M | 0.00 | Mr. Angelo William Lovallo Jr.,
48
Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer | 300.00K | 0.00 | Dr. Robert J. Israel M.D.,
56
Sr. VP of Medical Affairs & Clinical Research | 496.00K | 29.00K | Dr. William C. Olson Ph.D.,
50
Sr. VP of R&D | 394.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.09(2.22%) 4:00PM EDT|After Hours
:
4.15